---
title: Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines
  and patient-derived tumor organoids in the era of precision medicine
date: '2025-02-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39954414/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250216171018&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: We established a dynamic publicly available dataset with
  detailed genomic, transcriptomic, and pharmacological annotation of classical neuroblastoma
  cell lines as well as novel sharable NBL-PDOs, representing the heterogeneous landscape
  of neuroblastoma. We anticipate that in vitro drug screening will be complementary
  to genomic-guided precision medicine by supporting clinical decision making, thereby
  improving prognosis for all neuroblastoma patients in the ...'
disable_comments: true
---
CONCLUSION: We established a dynamic publicly available dataset with detailed genomic, transcriptomic, and pharmacological annotation of classical neuroblastoma cell lines as well as novel sharable NBL-PDOs, representing the heterogeneous landscape of neuroblastoma. We anticipate that in vitro drug screening will be complementary to genomic-guided precision medicine by supporting clinical decision making, thereby improving prognosis for all neuroblastoma patients in the ...